Skip to content

Francesca Pacitti

2 papers in the library · publishing 2026

Papers

Sort Most recent Most cited

Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder with Comorbid Treatment-Resistant Depression: A Six-Month Case Report

Psychiatry International September 10, 2026 Tommaso Barlattani, Giorgio Sernia, Chiara D’Amelio et al.

Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–compulsive symptoms was followed as a secondary observational outcome. Her...

Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole.

Journal of Affective Disorders July 28, 2026 Giacomo d'Andrea, Clara Cavallotto, Ottavia Susini et al.

Treatment-resistant depression (TRD) is a heterogeneous condition in which symptoms such as anhedonia, rumination, and anxiety contribute to persistent disability. Esketamine nasal spray (ESK-NS), accelerated repetitive transcranial magnetic stimulation (arTMS), and adjunctive brexpiprazole represent novel therapeutic options with distinct mechanisms, though their domain-specific effects in...

DOI: 10.1016/j.jad.2026.122333 (opens in new tab) Full text (opens in new tab) Accelerated rtms artms Brexpiprazole augmentation Treatment-resistant depression trd